BridgeMD
Study of KITE-753 Versus Axicabtagene Ciloleucel in People with Large B-Cell Lymphoma That Has Returned After Treatment (Relapsed) or Not Responded to Treatment (Refractory)
EU CTIS ID: 2025-524403-80-00
What this study is testing
To evaluate the efficacy of KITE-753 versus axicabtagene ciloleucel
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Men or women, 18 years or older
- Participants must have cancer that is refractory or relapsed within 12 months after completing initial treatment
- Participants must have at least one measurable tumor at study start
- Participants must have good enough physical functioning to perform daily activities with minimal assistance (ECOG: Eastern Cooperative Oncology Group performance status of 0, 1 or 2, meaning they can carry out daily activities with little or some assistance. ECOG is a tool that measures how cancer affects a patient’s ability to carry out day-to-day tasks)
- Participants must have adequate bone marrow, kidney, liver, heart, and lung function
- Female participants who can become pregnant must have a negative pregnancy test
You likely can't join if
- Participants will not be eligible if they have previously received cell-based therapy, have certain other cancers, have uncontrolled infections, have central nervous system involvement by lymphoma, have had a recent stroke or heart problems, or have certain immune system disorders. These restrictions help ensure the study is as safe as possible for participants.
- For more details on exclusion criteria, please refer to the study protocol
See the full eligibility criteria
- Men or women, 18 years or older
- Participants must have cancer that is refractory or relapsed within 12 months after completing initial treatment
- Participants must have at least one measurable tumor at study start
- Participants must have good enough physical functioning to perform daily activities with minimal assistance (ECOG: Eastern Cooperative Oncology Group performance status of 0, 1 or 2, meaning they can carry out daily activities with little or some assistance. ECOG is a tool that measures how cancer affects a patient’s ability to carry out day-to-day tasks)
- Participants must have adequate bone marrow, kidney, liver, heart, and lung function
- Female participants who can become pregnant must have a negative pregnancy test
- For more details on inclusion criteria, please refer to the study protocol
- Participants will not be eligible if they have previously received cell-based therapy, have certain other cancers, have uncontrolled infections, have central nervous system involvement by lymphoma, have had a recent stroke or heart problems, or have certain immune system disorders. These restrictions help ensure the study is as safe as possible for participants.
- For more details on exclusion criteria, please refer to the study protocol
The study team makes the final eligibility decision.
Where it's taking place
- Israel
- United Kingdom
- Korea, Republic of
- Canada
- Japan
- United States
- Australia
- Saudi Arabia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Israel; United Kingdom; Korea, Republic of; Canada; Japan; United States and 2 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.